David Mutch, MD

Gynecologic Oncology, Surgeon

Primary Academic Title

Professor, Obstetrics and Gynecology, Washington University School of Medicine

Research Interest

Cytokine activity against tumor cell mechanism of action; molecular genetics of endometrial and ovarian cancers; and RER mutations, LOH, cloning areas of loss on 10q and 1p. Principal Investigator, SPORE in Endometrial Cancer

Education

1980: MD, Washington University, St. Louis

Training

1980 - 1984: Resident, obstetrics and gynecology, Washington University, St. Louis
1984 - 1987: Fellow, gynecologic oncology, Duke University, Durham, N.C.

Board Certification

1988: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology
1989: American Board of Obstetrics and Gynecology, Gynecologic Oncology

Selected Research Publications

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Landen CN, Buckanovich RJ, Sill MW, [...] Mutch DG, [...] Bookman MA
J Clin Oncol 2024

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Mutch D, Voulgari A, Chen XM, [...] Yan Y
Cancer 2024

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Abu-Rustum NR, Yashar CM, Arend R, [...] Mutch D, [...] Espinosa S
J Natl Compr Canc Netw 2024

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.

Patel SP, Othus M, Chae YK, [...] Mutch D, [...] Kurzrock R
Clin Cancer Res 2024

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

Abu-Rustum NR, Yashar CM, Arend R, [...] Mutch D, [...] Espinosa S
J Natl Compr Canc Netw 2023

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.

Hagemann IS, Deng W, Zaino RJ, [...] Mutch DG
Gynecol Oncol 2023

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.

Compadre AJ, van Biljon LN, Valentine MC, [...] Mutch DG, [...] Mullen MM
Clin Cancer Res 2023

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Abu-Rustum N, Yashar C, Arend R, [...] Mutch D, [...] Aggarwal S
J Natl Compr Canc Netw 2023

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

You B, Purdy C, Copeland LJ, [...] Mutch D, [...] Burger RA
J Clin Oncol 2022

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Thiel KW, Devor EJ, Filiaci VL, Mutch D, [...] Leslie KK
J Clin Oncol 2022

Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).

Donovan HS, Sereika SM, Wenzel LB, [...] Mutch DG, [...] Ward SE
J Clin Oncol 2022

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.

Powell MA, Filiaci VL, Hensley ML, [...] Mutch DG, [...] Miller DS
J Clin Oncol 2022